Nob Hill Therapeutics, an early-stage pulmonary medical device and therapeutics company, has raised the first close of a $3 million Series A financing round. The round was led by new investor Tramway Venture Partners and included investments from TCA Venture Group and VIC Technology Venture Development (which founded NHT).
Read also – [Funding News] Abnormal Security Raises $250 Million Series D Funding
In connection with the financing, Chris Japp, Managing Partner of Tramway Venture Partners, will join Nob Hill’s Board of Directors. Sima Ghafari of TCA Venture Group will join as a Board Observer.
Read also – [Funding News] HubiFi Raises $2.5 Million Seed Funding Round
Nob Hill Therapeutics is developing new technologies and therapies for lung-related diseases that cannot be effectively treated today. The funds will support continued development of Nob Hill’s high-dose respiratory technology and therapeutics, including pre-IND studies.
Chris Japp said, “We are excited to work with the Nob Hill Therapeutics team and add them to the Tramway portfolio. Their respiratory technology and therapeutics have the potential to help millions of patients that currently do not have good treatment options for lung-related diseases.”
Noel Greenberger, CEO of NHT, added, “We continue to advance our goal of being the leading provider of high-dose lung delivery solutions. We look forward to working with our investors, who bring not only years of medical device and therapeutic experience, but pulmonary expertise too. With our investors’ support, we can accelerate our drive to address some of the most challenging pulmonary diseases.”
NHT has a patent-protected inhalation device technology capable of delivering high therapeutic doses directly to the lung. It is suitable for patients of all ages and inhalation capabilities, including patients with compromised lung function.
About Nob Hill Therapeutics
Nob Hill Therapeutics mission is to commercialize the first-of-its-kind dry powder nebulizer (DryNebTM ) inhalation drug delivery platform. NHT is focused on creating effective inhalation therapies to address lower respiratory tract infections (the 5th leading overall cause of death worldwide) and other deadly lung diseases.
